Bookmark

Add to MyYahoo RSS

Merck News

News on Merck (Ticker: MRK) continually updated from thousands of sources around the net.

11 hrs ago | BioSpace

Merck & Co., Inc. Announces Positive Outcome Of 3b Study For Kuvan

Merck Announces Positive Outcome of IIIb Study for Kuvan DARMSTADT, Germany, April 24, 2014 /PRNewswire/ -- -- Primary endpoint met in SPARK study: significant increase in phenylalanine tolerance demonstrated after 26 weeks of the study in children less than 4 years of age with phenylketonuria and responsive to Kuvan treated with Kuvan plus a ... (more)

Comment?

Related Topix: Biotech, Healthcare Industry, World News, Germany

Wed Apr 23, 2014

Drug Researcher

Merck & Co. contracts Catalent to make sublingual hayfever drugs

The US Food and Drug Administration approved MSD's drug Ragwitek - containing an extract of Ragweed - to treat hay fever with or without conjunctivitis last week, becoming the third allergen extract drug administered sublingually to be approved.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Food and Drug Administration, Hay Fever, Health, Outsourcing

Investopedia

These Biotech Pioneers Are Now On Sale

With those two factors in place, it's time to double up on your biotech research efforts, which is why I've been giving these stocks more ink than usual in recent weeks.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Novartis

Tue Apr 22, 2014

AmericanBankingNews.com

Merck & Co. Sets New 12-Month High at $58.23

Merck & Co. shares hit a new 52-week high during trading on Tuesday , AnalystRatings.NET reports.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Merck & Co.

Sys-Con Media

Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Global Clinical Trials Review, H1, 2014

Summary GlobalData's clinical trial report, "Chemotherapy Induced Acral Erythema Global Clinical Trials Review, H1, 2014" provides data on the Chemotherapy Induced Acral Erythema clinical trial scenario.

Comment?

Related Topix: Oncology, Medicine, Biotech, Healthcare Industry

Mon Apr 21, 2014

Seeking Alpha

3 Stocks To Capitalize On Advances In Hepatitis C Treatment

There has recently been a spate of announcements in the hepatitis C treatment space and doctors have generally welcomed the entry of more drugs to provide more treatment options.

Comment?

Related Topix: Hepatitis, Medicine, Health, Financial Markets, Biotech, Gilead Sciences, Healthcare Industry, Healthcare Law, Law, Bristol Myers Squibb

Thu Apr 17, 2014

Value Line

Drug Roundup - " April 17, 2014

There have been several noteworthy developments in the drug space recently, which will likely have a material impact on the companies in this sector and the markets they serve.

Comment?

Related Topix: Pfizer, Biotech, Medicine, Healthcare Industry, Teva Pharmaceutical Industries, Merck & Co., Eli Lilly, Bristol Myers Squibb

BioSpace

FDA OKs Merck & Co., Inc. Tablet To Reduce Ragweed Allergies

FDA Approves Merck's RAGWITEKa Sublingual Tablet as Immunotherapy to Treat Short Ragweed Pollen-Induced Allergic Rhinitis with or without Conjunctivitis in Adults RAGWITEK is the First and Only FDA Approved Sublingual Allergen Immunotherapy Tablet Indicated for the Treatment of Short Ragweed Pollen Allergies WHITEHOUSE STATION, N.J.-- --Merck , ... (more)

Comment?

Related Topix: Merck & Co., Biotech, Food and Drug Administration, Medicine, Healthcare Industry, Conjunctivitis, Health, Allergy, Immunology, Biology, Science

Freshnews

FDA Approves Merck's RAGWITEKa (Short Ragweed Pollen Allergen...

Merck , known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has approved RAGWITEK Tablet for Sublingual Use .

Comment?

Related Topix: Food and Drug Administration, Biotech, Medicine, Healthcare Industry, Conjunctivitis, Health, Allergy, Immunology, Biology, Science

ABC News

FDA OKs Merck Tablet to Reduce Ragweed Allergies

U.S. regulators have again approved a Merck & Co. tablet for gradually reducing seasonal allergies, this time for ragweed pollen.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Merck & Co., Whitehouse Station, NJ

The Papillion Times

FDA OKs Merck tablet to reduce ragweed allergies

Jenkins pleaded guilty in court Wednesday, then refused to accept prosecutors' accounts of the shootings.

Comment?

Related Topix: Healthcare Law, Law, Biotech, Medicine, Healthcare Industry, Nebraska, Blog News

The Miami Herald

FDA OKs Merck tablet to reduce ragweed allergies

U.S. regulators have again approved a Merck & Co. tablet for gradually reducing seasonal allergies, this time for ragweed pollen.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Merck & Co., Whitehouse Station, NJ

Spectroscopy

Udit Batra Appointed Merck Millipore President and CEO

Merck Millipore , the Life Sciences division of Merck, has appointed Udit Batra as President and CEO, responsible for overseeing the organization's worldwide operations effective 15 May 2014.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, World News, Germany, Engineering, Chemical Engineering, Science, Princeton University, University of Delaware, Massachusetts, Massachusetts Government

Wed Apr 16, 2014

Business Journal

Clinipace becomes a 'preferred provider,' starts acting like a big CRO

By reaching a preferred provider deal with a mid-market drug developer, Clinipace is starting to act like a much bigger contract research organization.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, GlaxoSmithKline, Merck & Co.

Wall St. Cheat Sheet

Is Merck a Hot Stock?

The company consists of four operating segments: the Pharmaceutical, Animal Health, Consumer Care, and Alliances segments, and one reportable segment in the Pharmaceutical segment.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry

CSRwire.com

Merck Renews Commitment to The Woodmont House at The Children's Inn at NIH

The Children's Inn at NIH today announced a $5 million contribution from the Merck Foundation to support and maintain programs and services at The Inn's Woodmont House, a transitional home for patients who are participating in pediatric research at the National Institutes of Health's Clinical Center.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry

The Motley Fool

2 Reasons Why Merck & Co. Is Crushing the Dow

Specifically, the Dow Jones is presently down around 1% on the year. That said, some of its components are still marching northward at a decent clip.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Cancer, Health, Healthcare Law, Law, Lung Cancer

This Is London

Reckitt Benckiser may list drugs arm separately

Durex condoms and Nurofen maker Reckitt Benckiser today said its A 1.3 billion drugs business could be split off and listed separately rather than sold outright.

Comment?

Related Topix: Household Products, Reckitt Benckiser, Biotech, Medicine, Healthcare Industry

Tue Apr 15, 2014

KDWN

FDA OKs Merck tablet to reduce grass allergies

Merck & Co. says the Food and Drug Administration has approved its new tablet for grass allergies, Grastek, for patients five to 65 years old.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Merck & Co., Food and Drug Administration, Whitehouse Station, NJ

The Motley Fool

Can Merck & Co. Inc. and Bristol-Myers Squibb Co. Dethrone Gilead Sciences Inc. for Hep C Combo?

Does Merck stand a chance? Merck has lagged the hepatitis C race, but the phase 2 results from its oral combination of MK-5172 and MK-8742 in genotype 1 patients are quite impressive.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Bristol Myers Squibb, Bloomsbury Publishing, Publishing, Media, Medarex, Bristol-Myers Squibb, Pharmaceuticals

•••
•••
•••
•••
•••

Seattle Jobs

•••
•••
•••
•••
•••